Valley National Advisers Inc Biomarin Pharmaceutical Inc Transaction History

Valley National Advisers Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$71.72 - $91.47 $4,231 - $5,396	-59 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$74.77 - $85.47 $523 - $598	-7 Reduced 10.61%	59 $5,000
Q2 2021 Aug 02, 2021	BUY	$75.51 - $84.79 $2,340 - $2,628	31 Added 88.57%	66 $6,000
Q1 2021 May 07, 2021	BUY	$74.73 - $90.69 $2,615 - $3,174	35 New	35 $3,000
Q3 2019 Nov 12, 2019	SELL	$67.4 - $85.11 $4,246 - $5,361	-63 Closed	0 $0
Q4 2018 Feb 25, 2019	BUY	$80.14 - $106.07 $5,048 - $6,682	63 New	63 $5,000
Q1 2018 Apr 19, 2018	SELL	$77.67 - $92.63 $1,320 - $1,574	-17 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $1,370 - $1,614	17	17 $2,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Valley National Advisers Inc, based on Form 13F filings with the SEC.

Stay updated on Valley National Advisers Inc with notifications on news.